Allergy Therapeutics plc (LON:AGY – Get Free Report) shares reached a new 52-week low on Tuesday. The company traded as low as GBX 4.50 and last traded at GBX 4.80, with a volume of 15626 shares traded. The stock had previously closed at GBX 4.75.
Allergy Therapeutics Price Performance
The stock has a market cap of £284.96 million, a P/E ratio of -4.64, a P/E/G ratio of -30.70 and a beta of 0.83. The company’s 50 day moving average price is GBX 5.21 and its 200-day moving average price is GBX 7.51. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
- Does Lemonade’s Growth Signal Profits Ahead?
- These 3 ETFs Could Benefit From the Parts of Inflation That Won’t Go Away
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
